An increasing number of patients have been described as having a number of Cystic Fibrosis Transmembrane conductance Regulator (CFTR) variants for which it lacks a clear genotype–phenotype correlation. We assesses the clinical features of patients bearing the S737F (p.Ser737Phe) CFTR missense variant and evaluated the residual function of CFTR protein on nasal epithelial cells (NEC).
A retrospective database was performed from individuals homozygous or compound heterozygous for the S737F variant followed in the Cystic Fibrosis (CF) Centre of Florence. We performed a nasal brushing in cooperating patients and compared the results with those of patients followed in the pediatric CF Centre of Naples.
9/295 (3%) subjects carrying at least S737F CFTR variant on one allele were identified. Patients were diagnosed in 7/9 cases by newborn screening and in two cases for dehydration with hypochloremic metabolic alkalosis; at diagnosis sweat chloride levels (SCL) were in the pathological range in only one case. After a mean follow up of 8,6 years (range 0,5–15,8), SCL were in the pathological range in 8/9 cases (mean age at CF diagnosis: 1,5 years), all patients were pancreatic sufficiency and respiratory function was normal. The gating activity on NEC was 15.6% and 12.7% in two patients compound heterozygous for W1282X and DelE22_24, while it was ranged between 6,2% and 9,8% in CF patients.
S737F is a CFTR mutation associated to hypochloremic alkalosis in childhood, mild CF phenotype in teenage years and a residual function of CFTR protein.
Djick FN, Fitzgerald DA. The impact of newborn screening and earlier intervention on the clinical course of cystic fibrosis. Paediatr Respir Rev. 2012;13:220–5. CrossRef
Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;53:S4–S14. CrossRef
Clinical and Laboratory Standard Institute (CLSI). Sweat testing: sample collection and quantitative analysis; approved guideline - third edition. CLSI document C34-A2 (ISBN 1–56238–713-8). Wayne: Clinical and Laboratory Standard Institute; 2009.
Terlizzi V, Tosco A, Tomaiuolo R, et al. Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. J Cyst Fibros. 2014;14:30–7.
Munck A, Mayell SJ, Winters V, Shawcross A, Derichs N, Parad R, et al. Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros. 2015;14:706–13. CrossRefPubMed
Castaldo G, Fuccio A, Cazeneuve C, et al. Detection of five rare cystic fibrosis mutations peculiar to southern Italy: implications in screening for the disease and phenotype characterization for patients with homozygote mutations. Clin Chem. 1999;45:957–62. PubMed
Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23:545–9. PubMed
Munck A, Delmas D, Audrézet MP, Lemonnier L, Cheillan D, Roussey M. Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process. J Med Screen. 2017:969141317692611. https://doi.org/10.1177/0969141317692611.
- S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy
Antonella Miriam Di Lullo
- BioMed Central